Growing evidence links the aggressiveness of non-Hodgkin's lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling. Here, we describe a dual-function molecule consisting of a clinically relevant TLR9 agonist (CpG7909) and a STAT3 inhibitor in the form of a high-affinity decoy oligodeoxynucleotide (dODN). The CpG-STAT3dODN blocked STAT3 DNA binding and activity, thus reducing expression of downstream target genes, such as MYC and BCL2L1, in human and mouse lymphoma cells. We further demonstrated that injections (i.v.) of CpG-STAT3dODN inhibited growth of human OCI-Ly3 lymphoma in immunodeficient mice. Moreover, systemic CpGSTAT3dODN administration induced complete regression of the syngeneic A20 lymphoma, resulting in long-term survival of immunocompetent mice. Both TLR9 stimulation and concurrent STAT3 inhibition were critical for immune-mediated therapeutic effects, since neither CpG7909 alone nor CpG7909 co-injected with unconjugated STAT3dODN extended mouse survival. The CpG-STAT3dODN induced expression of genes critical to antigen-processing/presentation and Th1 cell activation while suppressing survival signaling. These effects resulted in the generation of lymphoma cell-specific CD8/CD4-dependent T cell immunity protecting mice from tumor rechallenge. Our results suggest that CpG-STAT3dODN as a systemic/local monotherapy or in combination with PD1 blockade can provide an opportunity for treating patients with B cell NHL.
INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most prevalent, aggressive type of non-Hodgkin's lymphoma (NHL). [1] [2] [3] While chemo-immunotherapy improved outcome for advanced NHLs, a significant percentage of patients ultimately develops the progressive disease. 4 The STAT3 transcription factor is frequently activated in NHL, regulating cell survival and proliferation, and has been associated with poor survival of patients with aggressive lymphoma. [5] [6] [7] [8] [9] Mutations of upstream STAT3 regulators are common in DLBCL. 10 STAT3 activation has been linked to autocrine/paracrine stimulation by interleukin (IL)-6 in the tumor microenvironment. 11, 12 More universally, STAT3 is a central immune checkpoint regulator in cancer cells and tumor-associated immune cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). [13] [14] [15] [16] While an attractive target for cancer therapy, [17] [18] [19] direct pharmacological inhibition of STAT3 proved difficult, and despite many attempts, there are still no US Food and Drug Administration (FDA)-approved small-molecule STAT3 inhibitors. 20, 21 These challenges underscore the need for alternative strategies, such as oligonucleotide-based STAT3 inhibitors, 20, 22 and new methods for targeted oligonucleotide delivery. 23 To overcome these obstacles, we previously developed a strategy for the delivery of therapeutic oligonucleotides, such as STAT3 small interfering RNA (siRNA), specifically to Toll-like receptor 9 + (TLR9   +   ) immune cells, such as plasmacytoid dendritic cells (pDCs), B cells, 24, 25 and cancer cells. 19, [26] [27] [28] [29] TLR9 is also commonly expressed in many hematologic malignancies, including BCL. 30, 31 Multiple clinical trials in NHL demonstrated safety but only limited efficacy of TLR9 agonists. 25, 30 These difficulties can be, at least partly, ascribed to more recently described defects in TLR9 signaling in BCLs. Several studies have linked mutations in downstream TLR9 signaling (e.g., MYD88) or polymorphism in the TLR9 promoter to the pathogenesis of aggressive NHL 10, 32 or increased NHL incidence, 33 respectively. Based on these observations, we developed dual-function CpG-STAT3 inhibitors to generate growth-inhibitory and immuno-mediated effects against DLBCL. 
RESULTS

Optimization of the CpG-STAT3dODN Strategy for Targeting BCL Cells
We recently developed a strategy to deliver STAT3 decoy oligodeoxynucleotide inhibitor (STAT3dODN) into human myeloid cells after conjugation to the type-A TLR9 agonist, CpG ODN. 34 While
CpG(A)-STAT3dODN showed efficacy in targeting a variety of myeloid cell types, it showed moderate internalization by nonmalignant B cells and BCLs. To improve the targeting of BCL, we modified the targeting sequence to the well-characterized, B-type CpG7909 that was previously evaluated in clinical trials in NHL patients ( Figure 1A) . 35, 36 More extensive phosphorothioation (PS) of the new CpG(B)-STAT3dODN improved nuclease resistance of this conjugate, which showed an 82-hr half-life in the presence of human serum ( Figure S1 ), compared to the 63-hr half-life previously reported for CpG(A)-STAT3dODN. 34 Consistent with our previous study, 26 primary human and mouse B cells and myeloid cells quickly and efficiently internalized fluorescently labeled CpG(B)-STAT3dODN
Cy3 , but not STAT3dODN
Cy3 alone, even at a low 50-nM dose ( Figure 1B ).
Furthermore, human activated B cell-like type (ABC)-DLBCL and mouse A20 lymphoma cells internalized CpG(B)-STAT3dODN
Cy3 within 1-6 hr of incubation. The uptake of STAT3dODN alone was negligible, with the exception of the OCI-Ly3 cells, which internalized unconjugated decoy DNA, albeit less effectively ( Figure 1C ). Finally, we confirmed cytoplasmic localization of the CpG(B)-STAT3dODN after being internalized by target lymphoma cells, using phase-contrast and confocal microscopy ( Figure 1D ). Our results suggested that modified CpG(B)-STAT3dODN can effectively penetrate into immune and lymphoma cells, thereby enabling STAT3 targeting.
CpG(B)-STAT3dODN Inhibits the Transcriptional Activity of STAT3
Binding of the high-affinity decoy molecules to activated STAT3 dimers prevents downstream target gene transactivation. 20 We utilized electrophoretic mobility shift assays (EMSAs) to assess the effect of CpG(B)-STAT3dODN on STAT3 binding to a STAT3-specific radiolabeled high affinity mutant of the c-Fos sis-inducible element (hSIE) probe. As shown in Figure 2A , CpG(B)-STAT3dODN abrogated almost completely the STAT3 activity in primary mouse splenocytes and also in mouse and human BCL cells, A20 and OCI-Ly3, respectively. In contrast, both control CpG(B)-scrODN and CpG(B) ODN alone increased STAT3 activity, especially in mouse target cells, which is a known effect of TLR9 signaling. The TLR9/nuclear factor kB (NF-kB) signaling induces the expression of IL-6 and/or IL-10, which activate STAT3 to restrain immunostimulation as a negativefeedback effect. 12, [37] [38] [39] We further verified that the inhibition of STAT3 activity translates into reduced expression of downstream target proteins, such as BCL-X L and c-MYC, in human and mouse lymphoma cells. 40, 41 The protein levels of BCL-X L and c-MYC were strongly downregulated by CpG(B)-STAT3dODN but not by the unconjugated STAT3dODN or control CpG(B)-scrODN in A20 and even more pronouncedly in OCI-Ly3 lymphoma ( Figure 2B ). Correspondingly, CpG(B)-STAT3dODN induced dose-dependent cytotoxicity in STAT3-dependent OCI-Ly3 and TMD8 ABC-DLBCL cells in vitro, while it had minimal effect on SU-DHL-6 germinal center (GC)-DLBCL or A20 cells ( Figure 2C ; data not shown).
Next, we tested the feasibility of using this strategy for targeting STAT3 in vivo. Mice with established, subcutaneously engrafted (s.c.-engrafted) A20 lymphoma were treated using repeated daily intratumoral (IT) injections of 1 mg/kg CpG(B)-STAT3dODN, control CpG(B)-scrODN, or PBS. Whole tumors were harvested 1 day after the third injection to assess STAT3 activation using EMSAs. Figure S4 ). These results were further validated using the human gene-specific Nanostring assay on the total RNA isolated from whole OCI-Ly3 tumors treated using-similarly, as before-a short-term treatment with three IT injections of 1 mg/kg The uptake by non-malignant B cells was lower at 15%-25% and negligible for T cells in all locations, consistent with the in vitro uptake of CpG(B)-STAT3dODN ( Figure 1B) . Although intravenous injections resulted only in partial penetration of the BCL compartment, based on our previous study, 34 such an internalization rate can be sufficient for the induction of systemic antitumor immunity using CpG-STAT3 inhibitors. Thus, we next assessed the antitumor efficacy of CpG(B)-STAT3dODN administered systemically. BALB/c mice with disseminated A20
LUC were treated using, every other day, intravenous injections of 5 mg/kg CpG(B)-STAT3dODN, CpG(B)-scrODN, or CpG(B) alone or were treated with vehicle only (PBS). Mice were treated until day 25 and then monitored without further treatment using bioluminescent imaging and body condition scoring. Within 10 days, CpG(B)-STAT3dODN treatments arrested A20 LUC lymphoma progression ( Figure 4B ) and then led to complete lymphoma regression in 75% of mice ( Figure 4C ). In contrast, control CpG(B)-scrODN and clinically relevant CpG(B)/CpG7909 or CpG7909, co-injected in equimolar amounts with the unconjugated STAT3dODN, had minimal and only transient inhibitory effects on lymphoma progression ( Figures  4B and S5, respectively) . Importantly, all CpG(B)-STAT3dODN-treated mice (0/8) that survived the initial A20 challenge were resistant to the rechallenge using the same lymphoma cells, while all naive mice (8/8) showed A20 engraftment ( Figure 4D ). CpG(B)-STAT3dODN efficacy was also superior when compared to that of atovaquone, a recently described STAT3 inhibitor with activity against human multiple myeloma and acute myeloid leukemia (AML) ( Figure S6 ). 42 The extended therapeutic effect of the single 2-week treatment cycle using CpG(B)-STAT3dODN and its long-term protective antitumor effect were indicative of immune-mediated antitumor responses. To assess the contribution of directly cytotoxic and immune-dependent antitumor effects, we engrafted A20 LUC lymphoma into the immunodeficient NSG mice. Following the engraftment as verified by bioluminescent imaging (BLI), mice were treated for 2 weeks of daily injections of CpG(B)-STAT3dODN, CpG(B)-scrODN, or PBS alone ( Figure 4E ). The CpG(B)-STAT3dODN failed to eliminate tumors in NSG mice and only weakly improved their survival, similar to CpG(B)-scrODN. These results likely indicate the limited effect of TLR9 stimulation on innate immune cells, such as granulocytes/neutrophils still active in NSG mice, 19 while underscoring the crucial role of adaptive immune responses in generating durable lymphoma regression. We further verified the contribution of CD8 + and CD4 + T cells to these therapeutic effects, using antibody-mediated depletion. The CD8 + T cell neutralization had the strongest negative impact on the CpG(B)-STAT3dODN effect against A20 lymphoma ( Figure 5A ). In the absence of CD8 + T cells, lymphoma progression was accelerated compared to that of other treatment groups, and mouse survival did not differ from that of the control PBS-treated mice ( Figure 5B ). The CD4-specific cell depletion completely alleviated the late onset of CpG(B)-STAT3dODN-induced antitumor immunity at 2 weeks after treatment initiation ( Figure 5A ). However, it did not prevent the early delay in A20 lymphoma progression, which resulted in minimally extended animal survival ( Figure 5B ). In contrast, over half of CpG(B)-STAT3dODN-treated reference mice (CpG(B)-STAT3dODN/IgG) survived lymphoma challenge and remained tumor free for >80 days ( Figure 5B ). After confirming the essential role of T cell immunity in mediating CpG(B)-STAT3dODN effects in vivo, we assessed whether therapeutic efficacy of this strategy can be enhanced by blocking PD1/PD-L1 immune checkpoint regulation, which often results in the reduced activity of exhausted T cells. As shown in Figure 5C , systemic administration of CpG(B)-STAT3dODN or anti-PD1 antibodies as single agents showed comparable effects against A20 lymphoma, with $50% mouse survival. Importantly, the combination of both strategies strongly improved therapeutic outcome, with 90% survival of mice ( Figure 5C ). These results suggest that the presence and activity of T cells are critical for the overall antitumor activity of CpG(B)-STAT3dODN against BCL. processing/presentation, such as major histocompatibility complex (MHC) class I-related genes (e.g., H2-D1, H2-K1, Psmb9, Tap1, Tap2, and Tapbp) and class II-related genes (e.g., H2-DM1 and H2-DMb2), and modulated the essential regulators of T cell activation (e.g., Cd40/80/83/86, Foxp3, Icosl, and Il12a/b) or cytotoxic functions (Gzma/b, Ifnb1, Ifng, and Prf1) ( Figures 6A and 6B) . Expression of the several STAT3-controlled mediators of lymphoma cell proliferation and survival, including Bcl2l1, Bcl6, Casp3, Ccnd3, and Myc, was reduced ( Figure 6B ). These gene expression profiles were reflected by significant increase of both cytotoxic cell and Th1 cell scores, Figure S8 ). These results confirm that CpG(B)-STAT3dODN can be safe and well tolerated during repeated systemic administration. Finally, the immunostimulatory effect of CpG(B)-STAT3dODN on human PBMCs at low or high cell density was moderate, comparable with the effect of CpG(B) alone, and did not result in a "cytokine storm" ( Figure S9 ). 43 Overall, our results support the feasibility and safety of using the combination of TLR9 stimulation with STAT3 inhibition for treatment of BCLs. The CpG(B)-STAT3dODN strategy has the potential to augment therapeutic effects by combining direct cytotoxicity with strong CD8 + and CD4 + T cell-mediated antitumor immunity.
DISCUSSION
In this study, we demonstrate that a conjugate of STAT3 decoy inhibitor with TLR9 ligand, CpG(B)-STAT3dODN, provides an in vivo strategy for cell-selective delivery to BCL cells. Without the need for pharmacological formulation, the unformulated CpG(B)-STAT3dODN, injected locally or systemically, was effective in blocking STAT3 in lymphoma cells. www.moleculartherapy.org human DLBCL xenotransplants, inhibiting their growth by a direct cytotoxic/cytostatic effect. While the therapeutic efficacy of CpG(B)-STAT3dODN in immunocompetent mice relied mainly on the potent T cell-mediated antitumor immunity, it was, at least partly, supported by the direct antitumor effect. The exact contribution of indirect versus direct antitumor effects will be explored in our further studies in TLR9-deficient lymphoma models. Importantly, the dualfunction antitumor effects required the combination of TLR9 agonist (CpG ODN) with STAT3 inhibitor in one molecule and were not observed for CpG7909 ODN or STAT3 inhibitor when injected alone or even when co-injected. The STAT3 inhibition, through the reversible decoy effect, combined with concurrent TLR9 activation seemed sufficient for the induction of the lymphoma differentiation to antigen-presenting phenotype, thereby ensuring therapeutic antitumor efficacy.
Previous studies by other groups demonstrated that TLR9 agonists-such as CpG7909, used in our study-inhibit the growth of cultured BCL cells and stimulate their immunogenicity. 25, 30, 44 Preclinical studies in mice suggested that the increased immunogenicity of BCL cells can contribute to systemic antitumor immune responses generated by local administration of CpG ODNs, creating an effect of in situ vaccination. 45 However, these effects required 5-to 10-fold higher concentrations of TLR9 agonists and direct IT injections to achieve antitumor effects. 44, 46, 47 To overcome these limitations, TLR9 agonists in preclinical studies, and later in clinical trials, were combined with either chemotherapy, radiotherapy, or targeted antibody-based strategies (e.g., rituximab). 25, 47, 48 Our previous studies and current observations suggest that blocking STAT3 removes restraints on the potency of TLR9-driven immunostimulation. 26, 28, 38, 49 This is in agreement with an original report in mouse lymphoma cells that suggested the role of STAT3 in restricting BCL cell immunogenicity. 50 Importantly, while mutations may prevent direct effects of STAT3 inhibition on BCL cells, the increased activity of non-malignant antigen-presenting cells can be sufficient for the induction of antitumor immune responses. 51 Several small-molecule JAK inhibitors and STAT3 antisense oligonucleotides are currently in clinical trials for hematologic malignancies, including drug-resistant or relapsed BCL cells. 22, 52 Whether their efficacy partly relies on immune-mediated effects is not yet clear. The non-selective, systemic Jak/STAT inhibition potentially might impede IFN-mediated antitumor T cell immunity and/or generation of memory T cells. 11 In contrast, emerging clinical immunotherapies activate T cells by directly blocking immune checkpoint molecules, such as PD1, responsible for T cell exhaustion. Given that targeting PD1 has already shown promise in initial phase I/II clinical trials in patients with advanced-stage NHL, including DLBCL, these strategies are likely to benefit from the combination with immunogenic CpG(B)-STAT3dODN. 52 Therefore, TLR9-targeted delivery of STAT3 inhibitors, as single agents or in combination with T cell-based approaches, offers a novel strategy for safer and more effective immunotherapy of BCL and, potentially, other hematologic malignancies.
MATERIALS AND METHODS
Cells
PBMCs from anonymous healthy donors were collected in accordance with the Declaration of Helsinki under the institutional review board (IRB) protocol 13378 (City of Hope; COH). 19 Cell viability was >90%, as confirmed using flow cytometry. Mouse A20 and human OCI-Ly3 cells were from ATCC or DSMZ, respectively, and TMD8 and U2932 ABC-DLBCL cells were kindly provided by Dr. G. Inghirami (Weill Cornell Medicine, New York, NY, USA). Cells were cultured in RPMI 1640/10% fetal bovine serum (FBS) media. To generate A20 LUC and OCI-Ly3 LUC cells, parental cells were transduced with luciferase/mCherry using a lentiviral vector. 53 
Mice
All animal experiments were followed established institutional guidance and approved protocols from the institutional animal care and use committee (COH). BALB/c mice were purchased from the National Cancer Institute (Frederick, MD, USA). NOD/SCID/ IL-2RgKO (NSG) mice, originally from the Jackson Laboratory, were maintained at the COH. Mice were injected intravenously or s.c. with 5 Â 10 6 OCI-Ly3 LUC or A20 LUC in PBS, and lymphoma engraftment/progression was monitored using BLI on the AmiX (Spectral Instruments).
Oligonucleotides
All oligonucleotides were synthesized in the DNA/RNA Synthesis Core (COH) by linking CpG7909 to STAT3dODN in a manner similar to one previously described. 26 The resulting conjugates are shown below (x = single C3 unit; asterisks indicate phosphorothioation sites): For internalization/biodistribution studies, oligonucleotides were 3 0 -labeled using Cy3 fluorochrome.
EMSAs and Protein Detection
EMSAs to detect STAT3 DNA-binding activity were performed as described previously. 26 Briefly, 10 mg nuclear extracts were incubated with hSIE 32 P-labeled oligonucleotide probes specific to STAT3 (hSIE) 54 for supershift control using anti-STAT3 antibody (Santa Cruz Biotechnology). Western blot detection to detect STAT3, TLR9 stimulation combined with STAT3 inhibition generates A20 B cell-lymphoma-specific immune responses. Recall response to irradiated (100 Gy) A20 cells was assessed using single-cell suspensions prepared from tumor-draining lymph nodes from in vivo-treated mice as described above. Numbers of IFNg-secreting cells were assessed using an ELISPOT assay. Upper panel: representative images; bottom panel: bar graphs representing results from one of two independent experiments. Data indicate means ± SEM (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, ****p % 0.0001; FFPE, formalin-fixed, paraffin embedded; MFI, mean fluorescence intensity; NS, not significant.
pSTAT3, BCL-X L , c-Myc, and b-actin expression was performed as described earlier.
19
Cell Viability Assay 10 4 DLBCL lymphoma cell lines were seeded in 100 mL 1% FBS Iscove's Modified Dulbecco's Medium (IMDM) in a 96-well plate and incubated in the presence of designated reagent for 3 days. 10 mL Vita-Orange Cell Viability Reagent (Biotool, B34304) was added into each well, and the mixture was incubated at 37 C with 5% CO 2 for 4 hr. Optical density (OD) at 450 nm was detected using Citation3, with OD at 690 nm as reference.
Immune Assays
For extra-/intracellular staining, fluorochrome-labeled antibodies and previously described staining protocols were used (eBioscience). 17, 29 Data collected on the BD-Accuri C6 and BD-Fortessa (BD Biosciences) were analyzed using FlowJo software (TreeStar). The ELISPOT assay was performed following manufacturer's protocol (CellSciences), as described previously. 28 Immunohistochemistry using anti-CD8 antibody (eBioscience/4SM15) was performed as described previously 19 and was analyzed on the Observer II microscope (Zeiss). For confocal microscopy, cells were fixed in 2% paraformaldehyde (Electron Microscopy Sciences); then, nuclei were stained using DAPI (Sigma-Aldrich), www.moleculartherapy.org and slides were analyzed using an inverted confocal microscope (LSM880-Airyscan; Zeiss) and the LSM Image Browser (Zeiss, v.4.2.0.121). 27 
NanoString Analysis
Total RNA was extracted from whole OCI-Ly3 or A20 tumors using the mirVana miRNA Isolation Kit (Ambion). RNA quality was verified using the Bioanalyzer-2100 (Agilent). Gene expression was analyzed using the PanCancer Immune Profiling panel for human or mouse, XT-CSO-HIP1-12 or XT-CSO-MIP1-12, respectively, on the nCounter system (NanoStringTechnologies) following the manufacturer's recommendations. Results were analyzed using nSolver 3.0 software (NanoStringTechnologies) and automated normalization of raw data.
Statistical Analysis
An unpaired t test was used to calculate the two-tailed p value to estimate statistical significance of differences between two experimental groups. A one-way ANOVA plus Bonferroni posttest were applied to assess the statistical significance of differences between multiple treatment groups. The relationship between two groups was assessed using correlation and linear regression. The p and r 2 values are indicated in the figures with asterisks: *p < 0.05; **p < 0.01; ***p < 0.001. Data were analyzed using Prism v.6.03 software (GraphPad). 
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